IGF::OT::IGF:NIMH Toxicological Evaluation of Novel Ligands

NIMH新型配体毒理学评价计划的目的是加速新型配体在人类成像中的发现、开发和应用。该计划还将促进发现和开发用于临床研究的新型精神活性药物，并作为治疗精神障碍的潜在治疗药物。这一举措将提供一个关键的资源，补充NIMH？现有的精神活性药物筛选计划，用于中枢神经系统中受体、通道和转运蛋白结合试验中新型化合物的药理学表征，以及用于评估功能活性的生化试验。新配体毒理学评估计划也将补充加速开发用于人类研究的脑成像新PET和SPECT配体的倡议。这些活动的努力将得到协调，以建立一个管道，用于快速和具有成本效益的开发新的配体，用于精神障碍的临床研究。

The purpose of the NIMH Toxicological Evaluation of Novel Ligands Program is to accelerate the discovery, development, and application of novel ligands for imaging in humans. The program will also facilitate the discovery and development of novel psychoactive agents for clinical research and as potential therapeutic agents for the treatment of mental disorders. This initiative will provide a critical resource that complements NIMH?s existing Psychoactive Drug Screening Program for pharmacological characterization of novel compounds in binding assays for receptors, channels, and transporters in the central nervous system and in biochemical assays to assess functional activity. The Toxicological Evaluation of Novel Ligands Program will also complement the initiative to accelerate the Development of Novel PET and SPECT Ligands for Brain Imaging for use in human studies. Efforts of these activities will be coordinated to establish a pipeline for the rapid and cost-effective development of novel ligands for clinical studies of mental disorders.